about
Passive immunity in prevention and treatment of infectious diseasesStructural basis for differential neutralization of ebolavirusesAntigenic subversion: a novel mechanism of host immune evasion by Ebola virusNeutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against itEbolavirus glycoprotein structure and mechanism of entryComplex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light ChainStructure of the Ebola virus glycoprotein bound to an antibody from a human survivorTechniques and tactics used in determining the structure of the trimericebolavirusglycoproteinA shared structural solution for neutralizing ebolavirusesStructure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola VirusStructural and molecular basis for Ebola virus neutralization by protective human antibodiesAntibodies for biodefenseProgress towards the treatment of Ebola haemorrhagic fever.Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics.Ebola virus can be effectively neutralized by antibody produced in natural human infection.Neutralizing human Fab fragments against measles virus recovered by phage displayA novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virusSynthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challengeNature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.An update on the use of antibodies against the filoviruses.The secret life of viral entry glycoproteins: moonlighting in immune evasion.The multiple roles of sGP in Ebola pathogenesisEbola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy.Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.Potential vaccines and post-exposure treatments for filovirus infections.Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins.Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.Viewpoint: filovirus haemorrhagic fever outbreaks: much ado about nothing?Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway
P2860
Q24550699-ED84F47D-64BC-48E1-89ED-9017DA31B88EQ27014910-76957A3B-D6C9-431B-A2D0-3595F5075186Q27339643-8193F8E5-AF21-4F9D-825B-2E9A6A4A7C43Q27489891-3F58C997-B90E-4FD7-B67A-45D94DEE9DBAQ27490991-C9B02CF9-AAE5-46E5-A993-1A6DE60A6B76Q27649064-BA9E654A-8F71-4D23-B1E7-213F1E69DA6AQ27651112-574A17E0-C258-44E6-91D1-065F6466D422Q27658238-067BFBA6-5344-4C64-8A89-B404C01D572FQ27675675-93A995B3-7512-4982-B68F-FDF9FB41CBB3Q27676230-10CC73A5-1D82-4DC2-9396-9FBB8048BF76Q27704188-485DBF3C-2B6C-4027-BC89-CDBF878A847AQ28394941-87B4EDC9-7183-419A-B7F6-3D1038CCFE6BQ30230272-902CA1B6-2956-4906-BB1C-ECCB7B92327AQ30384726-FC0D3226-9EA7-4D35-9CFC-5EAA372D20C9Q30712477-28DAC424-B657-498C-938C-AAE6F480767FQ31032269-495C2902-C72E-4CE6-B293-1843FD5105E6Q31143293-0C67324B-DE20-4240-99A3-BA068A29090BQ33733844-C4AA174A-DCEB-431B-A528-73A3811533F6Q34361120-72323ED0-94F8-4697-8AA5-B6AF2095054DQ34434854-0231D02B-E5B7-4D04-A250-91BE084BCC2FQ34657170-B411CC51-7C58-4DE0-94BB-C3AF65D7BDC5Q34733547-DF5C01C4-15CD-4A20-89ED-A89B43E5797EQ34869463-52B9C040-2F7B-4954-84D0-0AE1CD1D7F27Q34969474-EB3A3684-FBC8-444D-A31E-5BD36CF3921DQ35107644-23D5EFD9-BAA0-4CD6-B293-68156E979C87Q35193047-3EA9B322-C667-481F-9974-8D60294BC311Q36023082-DF09A1BA-CC5A-4D24-9AF6-ADA08125A226Q36033286-85FFBD2E-F747-47DF-994A-25755E02C06AQ36379337-A13B5F95-BD48-4F81-85F3-C22198B4CBDBQ36404178-4071AEB9-4BD3-40CA-9056-A1BB5953624CQ37333887-BB34712F-9D5C-4A6B-958F-1455D9FEF808Q38847348-E8A2FDE9-8A75-4C08-826C-E86E46099442Q38914896-ECAC1869-D675-4CC4-B819-725F2E1E3D47Q39683688-928C688C-1F7F-4532-B819-3A4AA1E73042Q55669069-4214A7FA-20DA-4C8E-AD71-6AA8B92CDED2Q56766050-86597E31-E6F1-4720-817A-49654BEDB6FB
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Recombinant human monoclonal antibodies to Ebola virus.
@ast
Recombinant human monoclonal antibodies to Ebola virus.
@en
type
label
Recombinant human monoclonal antibodies to Ebola virus.
@ast
Recombinant human monoclonal antibodies to Ebola virus.
@en
prefLabel
Recombinant human monoclonal antibodies to Ebola virus.
@ast
Recombinant human monoclonal antibodies to Ebola virus.
@en
P2093
P356
P1476
Recombinant human monoclonal antibodies to Ebola virus.
@en
P2093
Maruyama T
Rodriguez LL
P304
P356
10.1086/514280
P407
P478
179 Suppl 1
P577
1999-02-01T00:00:00Z